Should Your Employer Have Access to Your Fitbit Data?

Should Your Employer Have Access to Your Fitbit Data?

A woman using a wearable device to track her fitness activities.

(© olegbreslavtsev/Fotolia)


Keep Reading Keep Reading
Junaid Nabi
Junaid Nabi, MD, MPH, is a physician, public health researcher, and a medical journalist. He currently manages several research projects at Brigham Health that include investigating provider- and hospital-level factors associated with racial and ethnic disparities in surgical oncology; evaluating the fiscal impact of consolidating care of complex patients; and, examining systematic factors that lead to opioid over-prescribing patterns after surgery. He has also undertaken research that examined the effect of health disparities that arise from social and political disenfranchisement and the relationship between trauma care and post-traumatic stress disorder (PTSD). Previously, he was a Fellow in Bioethics at Harvard Medical School Center for Bioethics where he studied bioethical issues in global healthcare delivery; role of bioethicists in Artificial Intelligence, Machine Learning, and other evolving technologies; and, emotional intelligence in bioethical analysis. He is a New Voices Fellow at The Aspen Institute, Washington, D.C., and a Fellow at Harvard Graduate School Leadership Institute, Boston.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.